| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | p27; Kip1; p27Kip1; AA408329; AI843786 |
| Entrez GeneID | 12576 |
| WB Predicted band size | Calculated MW: 22 kDa; Observed MW: 27 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Recombinant protein of mouse p27 KIP 1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3-4篇关于p27 Kip1抗体的参考文献及其简要摘要：
1. **"p27. a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21"**
- **作者**: Toyoshima H, Hunter T
- **摘要**: 该研究首次克隆并鉴定了p27 Kip1蛋白，揭示了其通过抑制G1期Cyclin-Cdk复合物(如Cyclin E-Cdk2)调控细胞周期进程的分子机制。
2. **"Decreased levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the breast"**
- **作者**: Catzavelos C et al.
- **摘要**: 通过免疫组化分析发现，乳腺癌组织中p27蛋白水平降低与肿瘤恶性程度升高及患者预后不良相关，提示p27作为肿瘤抑制因子的潜在临床价值。
3. **"Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas"**
- **作者**: Loda M et al.
- **摘要**: 研究证实，结直肠癌中p27蛋白的降解加速(通过泛素-蛋白酶体途径)导致其表达下调，且与肿瘤侵袭性和不良预后显著相关。
4. **"Monoclonal antibodies specific for p27Kip1: Immunohistochemical analysis of p27Kip1 expression in human tumors"**
- **作者**: Fero ML et al.
- **摘要**: 报道了针对p27 Kip1的单克隆抗体的开发与验证，展示了其在多种人类肿瘤组织中的免疫组化应用，为临床病理检测提供了可靠工具。
这些文献涵盖了p27 Kip1的功能研究、临床意义及抗体开发应用。
The p27 Kip1 antibody is a crucial tool in studying cell cycle regulation and cancer biology. p27 Kip1 (also known as cyclin-dependent kinase inhibitor 1B, CDKN1B) is a protein encoded by the CDKN1B gene and belongs to the Cip/Kip family of cyclin-dependent kinase (CDK) inhibitors. It plays a pivotal role in controlling the G1-to-S phase transition by binding to and inhibiting cyclin-CDK complexes, particularly cyclin E-CDK2 and cyclin D-CDK4/6. thereby arresting cell cycle progression. Its expression is regulated transcriptionally and post-translationally via phosphorylation, ubiquitination, and proteasomal degradation, often influenced by growth signals or stress conditions.
Antibodies targeting p27 Kip1 are widely used in research to detect its expression levels, localization, and interactions in tissues or cultured cells. These antibodies enable techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), helping to explore its role in cellular quiescence, differentiation, and tumor suppression. Reduced p27 levels are associated with poor prognosis in various cancers, as p27 acts as a tumor suppressor by limiting uncontrolled proliferation. However, paradoxical roles in cancer metastasis have also been reported, highlighting context-dependent functions.
Researchers utilize p27 Kip1 antibodies to investigate mechanisms of cell cycle dysregulation, therapeutic responses, and carcinogenesis. Specificity and cross-reactivity across species (e.g., human, mouse, rat) are key considerations when selecting these antibodies. Their applications span basic molecular biology, drug development, and clinical studies aiming to unravel p27's dual roles in growth inhibition and oncogenic processes.
×
